Justyna Siwy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7854460/publications.pdf Version: 2024-02-01



LUCTVNA SINAV

#	Article	IF	CITATIONS
1	Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. Journal of Proteome Research, 2009, 8, 268-281.	3.7	221
2	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	6.1	205
3	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 301-312.	11.4	166
4	Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11299-11304.	7.1	151
5	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 2011, 53, 875-884.	7.3	143
6	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics - Clinical Applications, 2010, 4, 464-478.	1.6	139
7	Urinary Proteomics for Prediction of Preeclampsia. Hypertension, 2011, 57, 561-569.	2.7	129
8	CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis. PLoS ONE, 2013, 8, e62837.	2.5	125
9	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 1563-1570.	0.7	106
10	Human urinary peptide database for multiple disease biomarker discovery. Proteomics - Clinical Applications, 2011, 5, 367-374.	1.6	105
11	Peptidomics and proteomics based on CEâ€MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis, 2019, 40, 2294-2308.	2.4	89
12	Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV). Science Translational Medicine, 2013, 5, 198ra106.	12.4	86
13	Urine as a source for clinical proteome analysis: From discovery to clinical application. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 884-898.	2.3	84
14	The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics, 2009, 9, 2108-2117.	2.2	82
15	Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration. PLoS ONE, 2014, 9, e96895.	2.5	74
16	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrology Dialysis Transplantation, 2017, 32, gfw239.	0.7	73
17	Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. PLoS ONE, 2013, 8, e53016.	2.5	70
18	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrology Dialysis Transplantation, 2017, 32, gfw337.	0.7	62

JUSTYNA SIWY

#	Article	IF	CITATIONS
19	Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. PLoS ONE, 2012, 7, e51334.	2.5	59
20	Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. American Journal of Clinical Nutrition, 2015, 101, 44-54.	4.7	58
21	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. PLoS ONE, 2010, 5, e13051.	2.5	51
22	Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice. PLoS ONE, 2013, 8, e76703.	2.5	50
23	Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease. PLoS ONE, 2013, 8, e67514.	2.5	43
24	Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Molecular Genetics and Metabolism, 2019, 126, 169-182.	1.1	41
25	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. Proteomics - Clinical Applications, 2018, 12, e1700163.	1.6	38
26	Proteomics of vitreous in neovascular age-related macular degeneration. Experimental Eye Research, 2016, 146, 107-117.	2.6	36
27	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2021, 37, 42-52.	0.7	36
28	Urinary Proteome Analysis at 5-Year Followup of Patients With Nonoperated Ureteropelvic Junction Obstruction Suggests Ongoing Kidney Remodeling. Journal of Urology, 2012, 187, 1006-1011.	0.4	31
29	Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy inÂmice. Kidney International, 2016, 90, 1045-1055.	5.2	31
30	Performance of different separation methods interfaced in the same MSâ€reflection TOF detector: A comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis, 2012, 33, 567-574.	2.4	29
31	Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. Proteomics - Clinical Applications, 2021, 15, e2000027.	1.6	29
32	Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports, 2018, 8, 5227.	3.3	28
33	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine, 2021, 36, 100883.	7.1	28
34	Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS. Molecules, 2021, 26, 7260.	3.8	28
35	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 811-818.	0.7	26
36	Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrology Dialysis Transplantation, 2017, 32, gfw243.	0.7	25

JUSTYNA SIWY

#	Article	IF	CITATIONS
37	Proteomic Candidate Biomarkers of Drug-Induced Nephrotoxicity in the Rat. PLoS ONE, 2012, 7, e34606.	2.5	24
38	Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. PLoS ONE, 2013, 8, e66682.	2.5	23
39	Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidaseâ€4 Inhibition: A Hypothesisâ€Generating Analysis from the MARLINAâ€₹2D Trial. Proteomics - Clinical Applications, 2019, 13, e1800144.	1.6	22
40	A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy. PLoS ONE, 2011, 6, e20534.	2.5	22
41	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics, 2013, 13, 2967-2975.	2.2	21
42	A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease. Proteomes, 2021, 9, 32.	3.5	21
43	Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion. PLoS ONE, 2016, 11, e0158001.	2.5	21
44	Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Scientific Reports, 2018, 8, 5584.	3.3	19
45	Comparative proteome and peptidome analysis of the cephalic fluid secreted by Arapaima gigas (Teleostei: Osteoglossidae) during and outside parental care. PLoS ONE, 2017, 12, e0186692.	2.5	18
46	A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves. Pediatric Nephrology, 2020, 35, 469-475.	1.7	17
47	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. The Lancet Healthy Longevity, 2021, 2, e690-e703.	4.6	17
48	Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. Nephrology Dialysis Transplantation, 2017, 32, 1468-1477.	0.7	16
49	CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVIDâ€19: A potential link to molecular pathophysiology?. Proteomics, 2021, 21, e2100133.	2.2	16
50	Proteomics and personalized medicine: a focus on kidney disease. Expert Review of Proteomics, 2019, 16, 773-782.	3.0	15
51	Collagen-Derived Peptides in CKD: A Link to Fibrosis. Toxins, 2022, 14, 10.	3.4	15
52	Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals. Current Protein and Peptide Science, 2014, 15, 23-35.	1.4	14
53	Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 2014, 44, 1104-1115.	3.4	14
54	Proteomic characterization of obesity-related nephropathy. CKJ: Clinical Kidney Journal, 2020, 13, 684-692.	2.9	14

JUSTYNA SIWY

#	Article	IF	CITATIONS
55	High-Resolution Proteome/Peptidome Analysis of Body Fluids by Capillary Electrophoresis Coupled with MS. Methods in Molecular Biology, 2013, 984, 153-165.	0.9	12
56	Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. PLoS ONE, 2022, 17, e0262667.	2.5	12
57	Polymerization-Incompetent Uromodulin in the Pregnant Stroke-Prone Spontaneously Hypertensive Rat. Hypertension, 2017, 69, 910-918.	2.7	11
58	Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. Scientific Reports, 2020, 10, 8291.	3.3	10
59	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine, 2021, 10, 1690.	2.4	10
60	Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. Expert Review of Molecular Diagnostics, 2019, 19, 853-856.	3.1	9
61	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	7
62	Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation. Liver International, 2015, 35, 1893-1901.	3.9	6
63	Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. Proteomes, 2021, 9, 49.	3.5	5
64	Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients. Nephrology Dialysis Transplantation, 2022, 37, 2014-2021.	0.7	4
65	SGLT2â€Inhibition reverts urinary peptide changes associated with severe COVIDâ€19: An inâ€silico proofâ€ofâ€principle of proteomicsâ€based drug repurposing. Proteomics, 2021, 21, e2100160.	2.2	3
66	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. Methods in Molecular Biology, 2020, 2067, 287-306.	0.9	3
67	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. Kidney International, 2021, 99, 1240-1241.	5.2	2